BiotechTube

Acitretin (also called U0279) + Placebo + Etanercept

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Oct 1, 2009 → Apr 1, 2010

NCT ID
NCT00832364

About Acitretin (also called U0279) + Placebo + Etanercept

Acitretin (also called U0279) + Placebo + Etanercept is a approved stage product being developed by GSK plc for Plaque Psoriasis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00832364. Target conditions include Plaque Psoriasis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00832364ApprovedWithdrawn

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
52
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77

Other Products from GSK plc

KetoconazoleApproved
84
Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene + clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazaroteneApproved
84
Duac® Gel / Differin® GelApproved
84
Epiduo Gel + Duac GelApproved
84
amoxicillinApproved
84